Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results
Company reported net ZILRETTA ®  (triamcinolone acetonide extended-release injectable suspension) sales of $22.5 million for full-year 2018 Since launch, 90% of target accounts have purchased or received samples of ZILRETTA and 69% of ordering accounts have placed reorders Company received Day 74
View HTML
Toggle Summary Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference
BURLINGTON, Mass. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 40 th Annual Raymond James Institutional Investors Conference in Orlando, Florida . Michael Clayman , M.D., President and Chief Executive Officer, is
View HTML
Toggle Summary Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage
Study conducted in collaboration with MIT showed that triamcinolone acetonide had protective effects on inflamed and/or injured cartilage in an established preclinical model Data presented in “late breaker” session at the recent 2019 Orthopaedic Research Society Annual Meeting BURLINGTON, Mass.
View HTML
Toggle Summary Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019
BURLINGTON, Mass. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Thursday, February 28, 2019 .
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy
Results from Phase 3b clinical trial indicate that repeat administration of ZILRETTA for osteoarthritis (OA) knee pain was generally safe and well-tolerated X-ray data at baseline and Week 52 showed ZILRETTA had no deleterious impact on cartilage or joint structure     The majority (74%) of
View HTML
Toggle Summary Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12
BURLINGTON, Mass. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has been invited to ring the Nasdaq opening bell on Tuesday, February 12, 2019 to commemorate the fifth anniversary of the company’s initial public offering (IPO).
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to 14 new employees for an aggregate of 51,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML
Toggle Summary Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
BURLINGTON, Mass. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009 , and she most recently served as the company’s Senior Vice President of Program
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 53,700 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019
Fourth-quarter 2018 revenue estimated to be approximately $9.5 million , an increase of 36% over the previous quarter Full-year 2018 revenue estimated to be approximately $22.5 million Flexion providing initial 2019 product revenue guidance of $65 to $80 million Conference call scheduled for
View HTML